clinical trial · NCT06718816
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Beijing Anlong Biopharmaceutical Co., Ltd.·—·recruiting·n = 21
Wet Age-related Macular Degeneration (wAMD)
brief summary
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
started
Dec 9, 2024
primary completion
Jun 30, 2029
completion
Jun 30, 2029
last updated
Dec 5, 2024
official title
A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol